NCT05222191 - Spironolactone in CKD Enabled by Chlorthalidone: PILOT | Biotech Hunter

Enrollment

24

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

December 12, 2023

Study Completion Date

December 12, 2023

Conditions

Renal InsufficiencyChronic Hypertension

Interventions

DRUG

Spironolactone

Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).

DRUG

Chlorthalidone

Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).

DRUG

Placebo

Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).

Trial Locations (1)

46202

RECRUITING

Richard L Roudebush VA Medical Center, Indianapolis